Fluvastatin AmelIorates aTHerosclerosis Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 140 participants.
Also called NCT01681199
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 140 participants
- Sponsor
- Registry
-
NCT01681199
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01681199. Allocation not applicable; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Fluvastatin AmelIorates aTHerosclerosis Study
- Acronym
- FAITH
- Condition
- Coronary Heart Disease
- Condition
- Atherosclerosis
- Intervention (Drug)
- Fluvastatin extended release tablet
- Lead sponsor
- Beijing Anzhen Hospital
- Collaborator
- Novartis
Record details
- Record id
cardio:ct-nct01681199- Content hash
9fccf022f03a0d71900096b4edf66db51020c94a66bb50d5e45f6c0f5bc15774